Atrium Therapeutics, Inc. 8-K

What Happened

• On May 14, 2026, Atrium Therapeutics, Inc. (NASDAQ: RNA) announced its financial results for the quarter ended March 31, 2026. The company furnished the full text of the related press release as Exhibit 99.1 to its Current Report on Form 8-K (Accession No. 0001193125-26-224238).

Key Details

• Item reported: 2.02 (Results of Operations and Financial Condition) — quarterly results announced.
• Date of announcement: May 14, 2026; quarter covered: ended March 31, 2026.
• Press release: furnished as Exhibit 99.1 to the Form 8-K.
• Item 9.01 exhibits: Exhibit 99.1 and the Inline XBRL cover page were furnished with the filing.

Why It Matters

• This 8-K signals Atrium has released its latest quarterly performance update — investors should read the furnished press release (Exhibit 99.1) for revenue, earnings/loss, cash position, and any operational or clinical updates. The Form 8-K itself provides notice of the results but investors should consult the press release and subsequent SEC filings for full financial details and context.